Haleon (LON:HLN) Price Target Raised to GBX 512

Haleon (LON:HLN) had its price target upped by Berenberg Bank from GBX 510 to GBX 512 in a research note released on Thursday, Marketbeat Ratings reports. Berenberg Bank currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 450 target price on shares of Haleon in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a research report on Wednesday, November 26th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 407.

Haleon Price Performance

Shares of HLN stock opened at GBX 376.60 on Thursday. The company has a debt-to-equity ratio of 53.60, a quick ratio of 0.93 and a current ratio of 0.87. The firm has a market capitalization of £33.54 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.49 and a beta of 0.25. The stock’s 50-day simple moving average is GBX 385.83 and its 200-day simple moving average is GBX 367.45. Haleon has a fifty-two week low of GBX 325.10 and a fifty-two week high of GBX 419.50.

Haleon (LON:HLN) last posted its quarterly earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.40%. As a group, equities analysts forecast that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.